Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study

Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study

(2014) M. A. Paggiosi et al.   OSTEOPOROSIS INTERNATIONAL

Adherence to raloxifene therapy: assessment methods and relationship with efficacy

(2013) J. Finigan et al.   OSTEOPOROSIS INTERNATIONAL

Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)

(2012) Richard M Jacques et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Bone turnover markers: use in osteoporosis

(2012) Kim Naylor et al.   Nature Reviews Rheumatology

Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice

(2012) I. Baxter et al.   OSTEOPOROSIS INTERNATIONAL

Treatment failure in osteoporosis

(2012) A. Diez-Perez et al.   OSTEOPOROSIS INTERNATIONAL

International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis

(2011) Samuel Vasikaran et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Bone turnover markers and bone mineral density response with risedronate therapy: Relationship with fracture risk and patient adherence

(2011) Richard Eastell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards

(2010) S. Vasikaran et al.   OSTEOPOROSIS INTERNATIONAL

A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy

(2009) A. Rogers et al.   BONE

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study

(2009) Ronald Emkey et al.   CLINICAL THERAPEUTICS

Utility of Biochemical Markers of Bone Turnover and Bone Mineral Density in Management of Osteoporosis

(2008) Samuel D. Vasikaran   CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES

Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club

(2008) P. Bergmann et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy

(2008) R. G. G. Russell et al.   OSTEOPOROSIS INTERNATIONAL